10-year

10-Year Anniversary Promotion (20% off)

Join GuruFocus Premium Membership Now for Only $279/Year

The largest discount in the last 10 years

Save up to $500 on Global Membership.

Don't Miss It !

Free 7-day Trial
All Articles and Columns »

Invesco European Growth Fund Comments on MorphoSys

November 11, 2013 | About:
Holly LaFon

Holly LaFon

276 followers
MorphoSys (XTER:MOR) is a German biotechnology company with a proprietary technology to develop human antibodies for specific diseases. The company signed two licensing deals (with GlaxoSmithKline PLC and Celgene Corp.) for its proprietary compounds, providing outside validation for its technology as well as upfront cash and future royalty payments.

From Invesco European Growth Fund’s third quarter 2013 commentary.

Rating: 0.0/5 (0 votes)

Comments

Please leave your comment:


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK